 |
|
|
| |
Predictors of HBeAg Loss in HBeAg-Positive Patients
With Chronic Hepatitis B During Treatment With TAF or TDF
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Calvin Q. Pan,1 Michael Kin Kong Li,2 Kwan Sik Lee,3 Rozalina I. Balabanska,4 John F. Flaherty,5 Kyungpil Kim,5 Robert P. Myers,5 G. Mani Subramanian,5 Djamal Abdurakhmanov,6 Mang M. Ma,7 Ho Bae,8 Kosh Agarwal9
1New Discovery LLC, New York, NY; 2Tuen Mun Hospital, Hong Kong; 3Gangnam Severance Hospital, Seoul, Korea; 4Tokuda Hospital Sofia, Bulgaria; 5Gilead Sciences, Inc., Foster City, CA;
6Sechenov First Moscow State Medical University, Moscow, Russia; 7University of Alberta, Edmonton, Canada; 8Asian Pacific Liver Center, St. Vincent Medical Center, Los Angeles, CA; 9Institute of Liver Studies, King's College Hospital, London, UK
References
1. Babusis D, et al. Mol Pharm 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40; 5. Sax P, et al. Lancet 2015;385:2606-15; 6. Fung S, et al. EASL 2012, poster 508; 7. Chan HLY, et al. Lancet Gastroenterol Hepatol In press.
|
| |
|
|
|
|
|
